AAM CEO Urges President-Elect Biden To Act On Access
As Dan Leonard Lays Out 2021 Outlook For US Generics And Biosimilars
Laying out the 2021 outlook for US generics and biosimilars, AAM president and CEO Dan Leonard has urged US president-elect Joe Biden and lawmakers in the US Congress to act to maximize savings and access to medicines.
You may also be interested in...
The AAM has insisted that the US Supreme Court should uphold the inter partes review framework, in an amicus brief filed as part of litigation that potentially threatens hundreds of IPR decisions.
The AAM has backed the draft Protecting Access to Affordable Medicines Act of 2020 introduced by the US House of Representatives members GK Butterfield, Billy Long and Tony Cardenas and has urged House members to co-sponsor the bill, which aims to protect low-cost generic medicines from a “misguided” Medicaid penalty.
The AAM’s 2019 report titled ‘Securing Our Access & Savings’ throws light on the monumental savings and benefits of generics and biosimilars for US patients and other stakeholders. The report urges policymakers to act to address obstacles to the off-patent industry and brings industry’s COVID-19 response in perspective again.